RGEN — REPLIGEN CORP
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 730272 ·
Last close
$181.62
Market Cap
$10.25B
52W High
$188.73
52W Low
$112.00
ADV30
1,241,555
Next earnings
2026-07-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 204,128,000 | 110,037,000 | 19,002,000 | 5,008,000 | 2,950,180,000 | 606,783,000 | 838,148,000 |
| Mar 2026 | — | — | — | — | — | — | — |
| Dec 2025 | 197,913,000 | 103,831,000 | 16,348,000 | 13,287,000 | 2,949,699,000 | 566,021,000 | 843,570,000 |
| Sep 2025 | 188,805,000 | 100,515,000 | 12,677,000 | 14,911,000 | 2,923,711,000 | 748,747,000 | 840,624,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$134,864,000
Investing CF
$-222,604,000
Financing CF
$-11,787,000
CapEx
$-24,711,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.73
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$469,589,000
Inventory
$186,604,000
Receivables
$157,710,000
ST Investments
$203,666,000
EBIT TTM
$74,300,000
Pretax Income TTM
$52,150,000
Interest Exp TTM
$22,150,000
Analysts
20
Yahoo Snapshot (yfinance, live)
Total Revenue
$785,100,992
EBITDA
$144,100,992
Free Cash Flow
$113,421,752
Enterprise Value
$10,102,677,504
Total Cash
$810,449,024
Total Debt
$690,942,016
Shares Out
56,435,621
Trailing EPS
$0.72
Book Value
$37.43
ROE
2.0%
ROA
1.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 738,256,000 | 41,560,000 | 48,894,000 | 2,949,699,000 | 843,570,000 | — | 117,417,000 |
| Dec 2024 | 634,439,000 | -31,923,000 | -25,514,000 | 2,829,666,000 | 856,948,000 | — | 175,394,000 |
| Dec 2023 | 632,362,000 | 17,134,000 | 35,596,000 | 2,831,185,000 | 866,340,000 | — | 113,918,000 |
| Dec 2022 | 801,536,000 | 195,941,000 | 185,959,000 | 2,531,600,000 | 620,900,000 | — | 172,083,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$2.64
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $155.00 · spot: $181.62 · call volume: 44 · put volume: 1,810Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KRYS | Krystal Biotech, Inc. | $10.11B | $341.72 | — |
| KYMR | Kymera Therapeutics, Inc. | $10.07B | $121.05 | — |
| TECH | BIO-TECHNE Corp | $11.28B | $72.39 | — |
| PCVX | Vaxcyte, Inc. | $9.21B | $61.87 | — |
| IMVT | Immunovant, Inc. | $8.95B | $43.32 | — |
News headlines (Yahoo Finance, 1h cache)
Repligen (RGEN) Stock Could Be 1% Overvalued Despite Its 45% Run
2026-08-20 10:08 · Yahoo
Unpacking Q2 Earnings: Repligen (NASDAQ:RGEN) In The Context Of Other Drug Development Inputs & Services Stocks
2026-08-17 11:34 · Yahoo
Repligen (RGEN) Is Up 16.2% After Revenue Rises But Profitability Compresses In Q2 2026
2026-08-10 03:19 · Yahoo
Acadia Gets European Commission Nod for Daybu in Rett Syndrome
2026-08-24 14:04 · Yahoo
3 High-Flying Stocks with Warning Signs
2026-08-24 12:01 · Yahoo
HALO Stock Rises 36% in a Month: Here's What You Should Know
2026-08-21 16:23 · Yahoo
3 Hyped Up Stocks We Keep Off Our Radar
2026-08-21 12:03 · Yahoo
MRK/MRNA's Personalized Cancer Therapy Delivers First Phase III Win
2026-08-20 15:09 · Yahoo
RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos
2026-08-20 14:16 · Yahoo
These Two Biotech Stocks Recorded Fresh Milestones Today – What’s Driving Today’s Gains?
2026-08-19 18:21 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.